Memphasys receives order for 1000 Felix cartridges across MENA markets

• Additional order from ITL for 1,000 Felix cartridges.
• Qatar’s largest IVF institution continues its repeat cartridge order program.
• Order covers new markets including The United Arab Emirates (UAE) and Kuwait.
• Additional orders to meet Turkish demand expected in July.

Memphasys (ASX:MEM) continues to expand the global market for its Felix system with new orders from the Middle East and North Africa (MENA) region for a major take-up of its unique Felix cartridges.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

The sales of Felix, an automated sperm separation device used in IVF, were led by International Technical Legacy, the company’s exclusive MENA commercialisation partner.

ITL has placed an order for 1,000 Felix cartridges, which includes 400 for Qatar and repeat orders from the UAE and Kuwait. A further 600-cartridge order has been confirmed for October to meet demand from existing clients.

Memphasys told shareholders that, together, these orders confirm Felix demand within the ITL network is broadening well beyond a single anchor site. Marjan Mikel, chair of the Memphasys commercialisation committee, said the order reflects a significant broadening and deepening of commercial activity across the MENA.

Leading the way there is Hamad Medical Corporation (HMC) – Qatar’s primary public health provider and the company’s anchor institutional reference customer – which is not only placing continued repeat cartridge orders but has separately ordered a second Felix console.

“This order demonstrates what genuine clinical adoption looks like in practice. HMC ordering a second console tells you everything about the strength of the clinical experience,” Mr Mikel said.

“And with UAE and Kuwait, joining we are seeing exactly the region-wide network effect that the ITL partnership was designed to generate. ITL is tracking well, and the pipeline across the MENA network continues to grow.

“The decision by HMC to invest in a second console is a meaningful commercial signal. It reflects institutional intent to scale Felix utilisation across HMC’s treatment program, effectively doubling throughput capacity and cementing Felix as a standard-of-care sperm preparation platform at Qatar’s largest fertility institution.”

Mr Mikel said the accelerated order trajectory provides Memphasys with strong early validation of recurring commercial demand across the MENA region and reinforces the company’s confidence in the scalability of the ITL partnership, contracted revenue visibility and ongoing cashflow planning.

The company expects additional Felix orders to meet ongoing demand for these regions throughout 2026.

MEM is steady at 0.4¢. Mkt cap $11.38M.

Join the discussion: See what HotCopper users are saying about Memphasys and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.